Last reviewed · How we verify
Improved Opioid-Tapering Instructions
Improved Opioid-Tapering Instructions is a Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Opioid dose reduction and discontinuation in patients on chronic opioid therapy.
This is a clinical protocol or instructional guideline for safely reducing opioid doses in patients, not a pharmaceutical drug with a molecular mechanism.
This is a clinical protocol or instructional guideline for safely reducing opioid doses in patients, not a pharmaceutical drug with a molecular mechanism. Used for Opioid dose reduction and discontinuation in patients on chronic opioid therapy.
At a glance
| Generic name | Improved Opioid-Tapering Instructions |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Improved Opioid-Tapering Instructions represent a standardized clinical management protocol developed by Brigham and Women's Hospital to guide healthcare providers in gradually reducing opioid medications in patients. This is a behavioral/clinical intervention tool rather than a pharmacological agent with a specific molecular target or mechanism of action.
Approved indications
- Opioid dose reduction and discontinuation in patients on chronic opioid therapy
Common side effects
- Withdrawal symptoms (anxiety, insomnia, muscle aches)
- Pain exacerbation during tapering
- Psychological distress
Key clinical trials
- Effect of Personalized Pain Coaches After Orthopaedic Surgery for Patients With Sports Medicine Injuries (NA)
- Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Improved Opioid-Tapering Instructions CI brief — competitive landscape report
- Improved Opioid-Tapering Instructions updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about Improved Opioid-Tapering Instructions
What is Improved Opioid-Tapering Instructions?
How does Improved Opioid-Tapering Instructions work?
What is Improved Opioid-Tapering Instructions used for?
Who makes Improved Opioid-Tapering Instructions?
What development phase is Improved Opioid-Tapering Instructions in?
What are the side effects of Improved Opioid-Tapering Instructions?
Related
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Therapeutic area: All drugs in Pain Management / Addiction Medicine
- Indication: Drugs for Opioid dose reduction and discontinuation in patients on chronic opioid therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing